Tailoring of interventional procedures for HCC patients-review article

Iranian Journal of Radiology

Volumn 7, Issue 3, 2010, Pages 129-143

  Ghanaati, H ^a   Alavian, S M ^b   Firouznia, K ^a   Abedini, M R ^a   Mohammadifard, M ^c   Jalali, A H ^a   Shakiba, M ^a   Ataee, R ^d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Baqiyatallah Research Center for Gastroentrology and Liver Disease   (Iran)

^c BIRJAND UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Carcinoma; Hepatocellular; Trans arterial chemoembolization

Indexed keywords

ACETIC ACID; ALCOHOL; ALPHA FETOPROTEIN; ANTIBIOTIC AGENT; CHLORPROMAZINE; CISPLATIN; DOXORUBICIN; EPIRUBICIN; IRINOTECAN; MITOMYCIN C; MITOXANTRONE; NARCOTIC AGENT; SORAFENIB; ZINOSTATIN; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

ABSCESS; BILE DUCT FISTULA; BILOMA; BLEEDING; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHOLANGITIS; COMPUTER ASSISTED TOMOGRAPHY; CRYOABLATION; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; ECHOGRAPHY; FEVER; FOLLOW UP; HEMOPERITONEUM; HEMOPHILIA; HUMAN; HYPOTHERMIA; INFECTION; LASER THERMOTHERAPY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER TRANSPLANTATION; LIVER TUMOR; NERVE INJURY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT SELECTION; PERCUTANEOUS MICROWAVE COAGULATION THERAPY; PLEURA EFFUSION; PNEUMOTHORAX; RADIOFREQUENCY ABLATION; RECURRENT DISEASE; REVIEW; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TUMOR ABLATION; TUMOR LYSIS SYNDROME; TUMOR SEEDING;

EID: 79951796550     PISSN: 17351065     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005 Mar-Apr;55(2):74-108.
2. Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am 2010 Dec;24(4):899-919.
3. Ataei B, Tayeri K, Kassaeian N, Farajzadegan Z, Babak A. Hepatitis B and C among patients infected with human immunodeficiencyvirusin Isfahan, Iran: seroprevalence and associated factors. Hepat Mon 2010;10(3):188-92.
4. Hashemi SA, Moghadami M, Lankarani KB, Alborzi A, Mahboudi A. The efficacy of hepatitis B vaccination among school age childrenin Southern Iran. Iran Red Cres Med J 2010;12(1):45-8.
5. Alavian SM, Fallahian F, Bagheri-Lankarani K. The Changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis 2007;16(4):403-6.
6. Alavian SM, Gooya MM, Hajarizadeh B, Esteghamati AR, Moeinzadeh AM, Haghazali M et al. Mass vaccination campaign against hepatitis B in adolescents in Iran: estimating coverage using administrative data. Hepat Mon 2009;9(3):189-95.
7. Alavian SM, Hajariazdeh B, Ahmadzad Asl M, Kabir A, Bagheri Lankarani K. Hepatitis B virus infection in Iran: a systematic review. Hepat Mon 2008;8(4):281-94.
8. Hajiani E, Hashemi S, Masjedizadeh A. Seroepidemiology of hepatitis B virus infection in Khuzestan province, Southwest of Iran. Hepat Mon 2009;9(1):34-8.
9. Khedmat H, Alavian SM, Miri SM, Amini M, Abolghasemi H, Hajibeigi B et al. Trends in seroprevalence of hepatitis B, hepatitis C, HIV, and syphilis infections in Iranian blood donors from 2003 to 2005. Hepat Mon 2009;9(1):24-8.
10. Khedmat H, Taheri S. Hepatitis B virus infection in Iran: current knowledge, future plans. Hepat Mon 2009;9(3):236-8.
11. Moradi A, Khodabakhshi B, Roshandel G, Kalavi K, Besharat S, Semnani S. Response to the hepatitis B virus vaccine in Iranian infants. Hepat Mon 2009;9(3):229-31.
12. Nokhodian Z, Kassaian N, Ataei B, Javadi AA, Shoaei P, Farajzadegan Z et al. Hepatitis B markers in Isfahan, central Iran: a population-based study. Hepat Mon 2009;9(1):12-6.
13. Uyar Y, Cabar C, Balci A. Seroprevalence of hepatiis B virus among pregnant women in northern Turkey. Hepat Mon 2009;9(2):146-9.
14. Umar M, Bushra H, Ahmad M, Khurram M, Usman S, Arif M et al. Hepatitis C in Pakistan: a review of avaiable data. Hepat Mon 2010;10(3):205-14.
15. Fani A, Fani I, Eshrati B, Samadian P, Fani P, Ghoreyshi Y et al. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B and C in Markazi province, Iran. Hepat Mon 2007;7(3):149-52.
16. Hajiani E, Masjedizadeh R, Hashemi J, Azmi M, Rajabi T. Risk factors for hepatocellular carcinoma in Southern Iran. Saudi Medical Journal 2005;26(6):974-7.
17. Shamszad M, Farzadegan H. Hepatitis B related cirrhosis and hepatocellular carcinoma in Iran. J Iran Med Council 1982;8:238.
18. Somi M, H. Hepatocellular carcinoma. Hepat Mon 2005;5(3):65-76.
19. Blum HE, Spangenberg HC. Hepatocellular carcinoma: an update. Arch Iran Med 2007;10(3):361-71.
20. Yu SC, Yeung DT, So NM. Imaging features of hepatocellular carcinoma. Clin Radiol 2004 Feb;59(2):145-56.
21. Primary liver cancer in Japan. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Liver Cancer Study Group of Japan. Ann Surg 1990 Mar;211(3):277-87.
22. Lee KH, O'Malley ME, Kachura JR, Haider M, Hanbidge A. Pictorial essay. Hepatocellular carcinoma: imaging and imaging-guided intervention. AJR Am J Roentgenol 2003 Apr;180(4):1015-22.
23. Harisinghani MG, Hahn PF. Computed tomography and magnetic resonance imaging evaluation of liver cancer. Gastroenterol Clin North Am 2002 Sep;31(3):759-76, vi.
24. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001 Sep;35(3):421-30.
25. Nicolau C, Bianchi L, Vilana R. Gray-scale ultrasound in hepatic cirrhosis and chronic hepatitis: diagnosis, screening, and intervention. Semin Ultrasound CT MR 2002 Feb;23(1):3-18.
26. Vogl TJ, Eichler K, Zangos S, Mack M, Hammerstingl R. Hepatocellular carcinoma: Role of imaging diagnostics in detection, intervention and follow-up. Rofo 2002 Nov;174(11):1358-68.
27. Wilson SR, Burns PN. An algorithm for the diagnosis of focal liver masses using microbubble contrast-enhanced pulse-inversion sonography. AJR Am J Roentgenol 2006 May;186(5):1401-12.
28. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995 Aug;22(2):432-8.
29. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998 Jan;27(1):273-8.
30. Dodd GD 3rd, Baron RL, Oliver JH 3rd, Federle MP. Spectrum of imaging findingsoftheliverinend-stagecirrhosis: Part II,focalabnormalities. AJR Am J Roentgenol 1999 Nov;173(5):1185-92.
31. Libbrecht L, Bielen D, Verslype C, Vanbeckevoort D, Pirenne J, Nevens F et al. Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl 2002 Sep;8(9):749-61.
32. Thng CH, Kuo YT. Hepatocellular carcinoma-issues in imaging. Cancer Imaging 2004 Oct 20;4(2):174-180.
33. Hayashi M, Matsui O, Ueda K, Kawamori Y, Kadoya M, Yoshikawa J et al. Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium. AJR Am J Roentgenol 1999 Apr;172(4):969-76.
34. Lee DH, Kim SH, Lee JM, Park HS, Lee JY, Yi NJ et al. Diagnostic performance of multidetector row computed tomography, superparamagnetic iron oxide-enhanced magnetic resonance imaging, and dual-contrast magnetic resonance imaging in predicting the appropriateness of a transplant recipient based on milan criteria: correlation with histopathological findings.Invest Radiol. 2009 Jun;44 (6):311-21.
35. Jung G, Breuer J, Poll LW, Koch JA, Balzer T, Chang S et al. Imaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent Gd-EOB-DTPA. Acta Radiol 2006 Feb;47(1):15-23.
36. Zech CJ, Reiser MF, Herrmann KA. Imaging of hepatocellular carcinoma by computed tomography and magnetic resonance imaging: state of the art. Dig Dis 2009;27(2):114-24.
37. Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology 2009 Feb;250(2):466-73.
38. Ghanaati H, Firouznia K, Motevalli M, Mirdamadi L, Jalali AH. Fluoroscopic versus conventional computed tomography-guided biopsy. Iran J Radiol 2008;5(1):39-42
39. Nassiri Toosi M, Ghanaati H, Azmoudeh Ardalan F, Agdarkosh H, Safai SR et al. Assessment of safety and efficacyoftransjugularliverbiopsyas a diagnostic method in adult patients with congenital bleeding disorders with HCV infection. Iran J Radiol 2004;2(1-2):73-9.
40. Sherman M. Modern Approach to Hepatocellular Carcinoma. Curr Gastroenterol Rep 2011 Feb,13(1) 49-55.
41. Mendizabal M, Reddy KR. Current management of hepatocellular carcinoma. Med Clin North Am 2009 Jul;93(4):885-900, viii.
42. Kuzuya T, Tsuchiya K, Izumi N. Efficacyofsorafenib,moleculartargeting drug, for advanced hepatocellular carcinoma. Gan To Kagaku Ryoho 2010 Oct;37(10):1883-86.
43. Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003 May;52 Suppl 3:iii 1-8.
44. Guan YS, Sun L, Zhou XP, Li X, Zheng XH. Hepatocellular carcinoma treated with interventional procedures: CT and MRI follow-up. World J Gastroenterol 2004 Dec 15;10(24):3543-8.
45. Guan YS, Liu Y. Interventional treatments for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2006 Nov;5(4):495-500.
46. Di Stasi M, Buscarini L, Livraghi T, Giorgio A, Salmi A, De Sio I et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma. A multicenter survey of evaluation practices and complication rates. Scand J Gastroenterol 1997 Nov;32(11):1168-73.
47. Hasegawa S, Yamasaki N, Hiwaki T, Sako K, Komorizono Y, Baba Y et al. Factors that predict intrahepatic recurrence of hepatocellular carcinoma in 81 patients initially treated by percutaneous ethanol injection. Cancer 1999 Nov 1;86(9):1682-90.
48. Ohnishi K, Ohyama N, Ito S, Fujiwara K. Small hepatocellular carcinoma: treatment with US-guided intratumoral injection of acetic acid. Radiology 1994 Dec;193(3):747-52.
49. Ohnishi K, Yoshioka H, Ito S, Fujiwara K. Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology 1998 Jan;27(1):67-72.
50. Huo TI, Huang YH, Huang HC, Wu JC, Lee PC, Chang FY et al. Fever and infectious complications after percutaneous acetic acid injection therapy for hepatocellular carcinoma: incidence and risk factor analysis. J Clin Gastroenterol 2006 Aug;40(7):639-42.
51. Georgiades CS, Hong K, Geschwind JF. Radiofrequency ablation and chemoembolization for hepatocellular carcinoma. Cancer J 2008 Mar-Apr;14(2):117-22.
52. Iannitti DA, Dupuy DE, Mayo-Smith WW, Murphy B. Hepatic radiofrequency ablation. Arch Surg 2002 Apr;137(4):422-6.
53. Kudo M. Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010. Oncology 2010 Jul;78 Suppl 1:113-24.
54. Allgaier HP, Galandi D, Zuber I, Blum HE. Radiofrequency thermal ablation of hepatocellular carcinoma. Dig Dis 2001;19(4):301-10.
55. Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 2009 Feb;104(2):514-24.
56. Gasparini D, Sponza M, Marzio A, Zanardi R, Bazzocchi M, Cemal Y. Combined treatment, TACE and RF ablation, in HCC: preliminary results. Radiol Med 2002 Nov-Dec;104(5-6):412-20.
57. Ferrari FS, Megliola A, Scorzelli A, Stella A, Vigni F, Drudi FM et al. Treatment of small HCC through radiofrequency ablation and laser ablation. Comparison of techniques and long-term results. Radiol Med 2007 Apr;112(3):377-93.
58. Camma C, Di Marco V, Orlando A, Sandonato L, Casaril A, Parisi P et al. Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. J Hepatol 2005 Apr;42(4):535-40.
59. Georgiades CS, Hong K, Geschwind JF. Pre- and postoperative clinical care of patients undergoing interventional oncology procedures: a comprehensive approach to preventing and mitigating complications. Tech Vasc Interv Radiol 2006 Sep;9(3):113-24.
60. Kasugai H, Osaki Y, Oka H, Kudo M, Seki T. Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: an analysis of 3,891 ablations in 2,614 patients. Oncology 2007;72 Suppl 1:72-5.
61. Seki T, Wakabayashi M, Nakagawa T, Itho T, Shiro T, Kunieda K et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer 1994 Aug 1;74(3):817-25.
62. Lu MD, Chen JW, Xie XY, Liu L, Huang XQ, Liang LJ et al. Hepatocellular carcinoma: US-guided percutaneous microwave coagulation therapy. Radiology 2001 Oct;221(1):167-72.
63. Horigome H, Nomura T, Saso K, Itoh M. Standards for selecting percutaneous ethanol injection therapy or percutaneous microwave coagulation therapy for solitary small hepatocellular carcinoma: consideration of local recurrence. Am J Gastroenterol 1999 Jul;94(7):1914-7.
64. Solbiati L, Goldberg SN, Ierace T, Livraghi T, Meloni F, Dellanoce M et al. Hepatic metastases: percutaneous radio-frequency ablation with cooled-tip electrodes. Radiology 1997 Nov;205(2):367-73.
65. Solbiati L, Ierace T, Goldberg SN, Sironi S, Livraghi T, Fiocca R et al. Percutaneous US-guided radio-frequency tissue ablation of liver metastases: treatment and follow-up in 16 patients. Radiology 1997 Jan;202(1):195-203.
66. Seki T, Tamai T, Nakagawa T, Imamura M, Nishimura A, Yamashiki N et al. Combination therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatocellular carcinoma. Cancer 2000 Sep 15;89(6):1245-51.
67. Gough-Palmer AL, Gedroyc WM. Laser ablation of hepatocellular carcinoma-a review. World J Gastroenterol 2008 Dec 21;14(47):7170-4.
68. Thomsen S. Pathologic analysis of photothermal and photomechanical effects of laser-tissue interactions. Photochem Photobiol 1991 Jun;53(6):825-35.
69. Steger AC, Lees WR, Walmsley K, Bown SG. Interstitial laser hyperthermia: a new approach to local destruction of tumours. BMJ 1989 Aug 5;299(6695):362-5.
70. Amin Z, Donald JJ, Masters A, Kant R, Steger AC, Bown SG et al. Hepatic metastases: interstitial laser photocoagulation with real-time US monitoring and dynamic CT evaluation of treatment. Radiology 1993 May;187(2):339-47.
71. Lau WY, Leung TW, Yu SC, Ho SK. Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg 2003 Feb;237(2):171-9.
72. Eichler K, Mack MG, Straub R, Engelmann K, Zangos S, Woitaschek D et al. [Oligonodular hepatocellular carcinoma (HCC): MR-controlled laser-induced thermotherapy]. Radiologe 2001 Oct;41(10):915-22.
73. Pacella CM, Bizzarri G, Francica G, Forlini G, Petrolati A, Valle D et al. Analysis of factors predicting survival in patients with hepatocellular carcinoma treated with percutaneous laser ablation. J Hepatol 2006 May;44(5):902-9.
74. Vogl TJ, Straub R, Eichler K, Woitaschek D, Mack MG. Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: experience with complications in 899 patients (2,520 lesions). Radiology 2002 Nov;225(2):367-77.
75. Arienti V, Pretolani S, Pacella CM, Magnolfi F, Caspani B, Francica G et al. Complications of laser ablation for hepatocellular carcinoma: a multicenter study. Radiology 2008 Mar;246(3):947-55.
76. Cooper IS. Cryogenic surgery. N Engl J Med 1963;268(14):743-9.
77. McCarty TM, Kuhn JA. Cryotherapy for liver tumors. Oncology 1998 Jul;12(7):979-87.
78. Mascarenhas BA, Ravikumar TS. Experimental basis for hepatic cryotherapy. Semin Surg Oncol. 1998 Mar;14(2):110-5.
79. Wong WS, Patel SC, Cruz FS, Gala KV, Turner AF. Cryosurgery as a treatment for advanced stage hepatocellular carcinoma: results, complications, and alcohol ablation. Cancer 1998 Apr 1;82(7):1268-78.
80. Weaver ML, Atkinson D, Zemel R. Hepatic cryosurgery in treating colorectal metastases. Cancer 1995 Jul 15;76(2):210-4.
81. Zhou XD, Tang ZY. Cryotherapy for primary liver cancer. Semin Surg Oncol 1998 Mar;14(2):171-4.
82. Adam R, Hagopian EJ, Linhares M, Krissat J, Savier E, Azoulay D et al. A comparison of percutaneous cryosurgery and percutaneous radiofrequency for unresectable hepatic malignancies. Arch Surg 2002 Dec;137(12):1332-9.
83. Crews KA, Kuhn JA, McCarty TM, Fisher TL, Goldstein RM, Preskitt JT. Cryosurgical ablation of hepatic tumors. Am J Surg 1997 Dec;174(6):614-7.
84. Maleux G, van Malenstein H, Vandecaveye V, Heye S, Vaninbroukx J, Nevens F et al. Transcatheter chemoembolization of unresectable hepatocellular carcinoma: current knowledge and future directions. Digestive diseases (Basel, Switzerland). 2009;27(2):157-63.
85. Lau WY, Yu SC, Lai EC, Leung TW. Transarterial chemoembolization for hepatocellular carcinoma. J Am Coll Surg 2006 Jan;202(1):155-68.
86. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007 Jan-Feb;30(1):6-25.
87. Vogl TJ, Naguib NN, Nour-Eldin NE, Rao P, Emami AH, Zangos S et al. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol 2009 Dec;72(3):505-16.
88. Plentz RR, Lankisch TO, Bastürk M, Müller CCM, Kirchhoff T, Gebel M et al. Prospective nalysis of german patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization with or without prophylactic antibiotic therapy. J Gastroenterol Hepatol 2005 Jul;20(7):1131-9.
89. VanderWalde AM, Marx H, Leong L. Liver abscess as a complication of hepatic transarterial chemoembolization: a case report, literature review, and clinical recommendations. Gastrointest Cancer Res 2009 Nov;3(6):247-51.
90. Jaeger HJ, Mehring UM, Castañeda F, Hasse F, Blumhardt G, Loehlein D et al. Sequential transarterial chemoembolization for unresectable advanced hepatocellular carcinoma. Cardiovasc Intervent Radiol 1996 Nov-Dec;19(6):388-96.
91. Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002 Jul;224(1):47-54.
92. Gadaleta CD, Ranieri G. Trans-arterial chemoembolization as a therapy for liver tumours: New clinical developments and suggestions for combination with angiogenesis inhibitors. Crit Rev Oncol Hematol 2010 Nov 8. [Epub ahead of print]. DOI: 10.1016/j.critrevonc.2010.10.005.
93. Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol 2009 Sep-Oct;10(5):425-34.
94. Reidy DL, Schwartz JD. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-I: hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinoma. Anticancer Drugs 2004 Jun;15(5):427-37.
95. Lladó L, Virgili J, Figueras J, Valls C, Dominguez L, Rafecas A et. al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 2000;88(1):50-7.
96. O'Suilleabhain CB, Poon RTP, Yong JL, Ooi GC, Tso WK, Fan ST. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Bri J Surg 2003;90:325-31.